Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren’t automatically worth investing in just because they provide essential medical services. Only those that can keep up with the changing nature of the industry can hope to deliver excellent returns over the long run.
There are many such stocks on the market. Let’s consider two that specialize in developing medical devices: DexCom (NASDAQ: DXCM) and Intuitive Surgical (NASDAQ: ISRG). These healthcare leaders are both well-positioned to deliver outsized returns in the next decade. Let’s see why.
Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
DexCom has encountered some issues lately. The company’s results in the second and third quarters were not strong. Unimpressive revenue growth, partly due to more consumers taking advantage of rebates than projected, harmed its performance.
However, DexCom still has attractive prospects. Its continuous glucose monitoring (CGM) systems are much more convenient for diabetes patients than manual blood glucose meters. Yet worldwide penetration of CGM was as low as 1% at the beginning of the year.
With DexCom actively seeking to enter new territories to expand its addressable market, the company has a vast runway for growth. Also, it recently expanded its market in the U.S. with an over-the-counter CGM option, Stelo, for people not using insulin. Patients with prediabetes or type 2 diabetes are eligible for Stelo.
Furthermore, thanks to DexCom’s leadership in the CGM market and its ecosystem of diabetes patients, other companies have developed devices and apps compatible with DexCom’s, such as insulin pumps and diabetes pens. The more people within DexCom’s ecosystem, the more attractive it becomes to third-party device and app developers, which will attract even more patients. In other words, it’s building a network effect, a powerful competitive advantage.
The company’s financial results and stock performance have been on a tear over the past decade, thanks to the increased adoption of CGM technology:
There’s far more room to run in the next decade, so DexCom can still deliver market-beating returns. It’s not too late to invest in the stock.
Intuitive Surgical is the leader in the robotic-assisted surgery (RAS) market. The healthcare leader is best known for its da Vinci system, a device that helps physicians perform minimally invasive surgeries thanks to tiny, highly maneuverable instruments. In March, the U.S. Food and Drug Administration cleared the fifth generation of Intuitive’s crown jewel, a testament to the company’s continued emphasis on innovation.
